Malignant ascites is a severe complication of many types of human cancer. Animal and clinical
analyses have shown that angiogenesis plays a critical role in the formation of malignant
ascites. Therefore, drugs such as apatinib that target angiogenesis may control the
development of malignant ascites. The study is to evaluate the efficacy and safety of
apatinib in patients with refractory malignant ascites.